期刊
ANTIBIOTICS-BASEL
卷 12, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/antibiotics12030437
关键词
colistin; quantification methods; drug stability; pharmacokinetics; drug monitoring
The emerging resistance of Gram-negative bacteria is a global problem that has led to the reintroduction of colistin as a therapeutic option. However, there are still many questions regarding the safety and efficacy of colistin. This review summarizes the available literature on the use of colistin in critically ill patients, focusing on stability, pharmacokinetics, plasma concentration determination methods, and therapeutic drug monitoring benefits and limitations. Based on these findings, the gaps in knowledge are identified, and future research directions are suggested.
The emerging resistance of Gram-negative bacteria is a growing problem worldwide. Together with the financial cost, limited efficacy, and local unavailability of newer antibiotics or their combinations, it has led to the reintroduction of colistin as a therapeutic alternative. Despite its protracted development and availability on the market, there is now a complex maze of questions surrounding colistin with a more or less straightforward relationship to its safety and efficacy. This review aims to offer a way to navigate this maze. We focus on summarizing the available literature regarding the use of colistin in critically ill patients, particularly on stability, pharmacokinetics, methods for determining plasma concentrations, and therapeutic drug monitoring benefits and limitations. Based on these data, we then highlight the main gaps in the available information and help define directions for future research on this drug. The first gap is the lack of data on the stability of intravenous and nebulization solutions at clinically relevant concentrations and under external conditions corresponding to clinical practice. Furthermore, pharmacokinetic-pharmacodynamic parameters should be validated using standardized dosing, including a loading dose. Based on the pharmacokinetic data obtained, a population model for critically ill patients should be developed. Finally, the interference of colistin with extracorporeal methods should be quantified.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据